Physician profile
Eric Kyndall Smith
NPI 1295767101
$602.67
in general payments reported to CMS, 2019-2025
11 companies · $76.52 in 2025
The $76.52 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $58.36 · 2021: $115 · 2022: $55.55 · 2024: $47.29 · 2025: $76.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $128.66 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.18 | 2024-2025 | Caplyta |
| Alcon Vision LLC | $90.20 | 2019-2022 | |
| Allergan, INC. | $79.91 | 2019 | |
| Aerie Pharmaceuticals, INC. | $76.63 | 2021 | |
| Omeros Corporation | $32.69 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $31.65 | 2020-2022 | |
| Lundbeck LLC | $29.63 | 2025 | Rexulti |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Rayner Intraocular Lenses Limited | $13.64 | 2022 | |
| Iridex Corporation | $8.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.